Expression of mRNA encoding the macrophage colony-stimulating factor receptor (c-fms) is controlled by a constitutive promoter and tissue-specific transcription elongation

Citation for published version:
Yue, X, Favot, P, Dunn, TL, Cassady, AI & Hume, DA 1993, 'Expression of mRNA encoding the macrophage colony-stimulating factor receptor (c-fms) is controlled by a constitutive promoter and tissue-specific transcription elongation' Molecular and Cellular Biology, vol 13, no. 6, pp. 3191-201.

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Early version, also known as pre-print

Published In:
Molecular and Cellular Biology

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Expression of mRNA Encoding the Macrophage Colony-Stimulating Factor Receptor (c-fms) Is Controlled by a Constitutive Promoter and Tissue-Specific Transcription Elongation

XIE YUE, PAULA FAVOT, TIMOTHY L. DUNN, A. IAN CASSADY, AND DAVID A. HUME*

Centre for Molecular Biology and Biotechnology, University of Queensland, Brisbane, Queensland 4072, Australia

Received 16 November 1992/Returned for modification 2 February 1992/Accepted 1 March 1993

The gene encoding the receptor for macrophage colony-stimulating factor 1 (CSF-1), the c-fms proto-oncogene, is selectively expressed in immature and mature mononuclear phagocytes and trophoblasts. Exon 1 is expressed only in trophoblasts. Isolation and sequencing of genomic DNA flanking exon 2 of the murine c-fms gene revealed a TATA-less promoter with significant homology to human c-fms. Reverse transcriptase primer extension analysis using exon 2 primers identified multiple clustered transcription initiation sites. Their position was confirmed by RNase protection. The same primer extension products were detected in equal abundance from macrophage or nonmacrophage sources of RNA. c-fms mRNA is acutely down-regulated in primary macrophages by CSF-1, bacterial lipopolysaccharide (LPS), and phorbol myristate acetate (PMA). Each of these agents reduced the abundance of c-fms RNA detectable by primer extension using an exon 3 primer without altering the abundance of presumptive short c-fms transcripts detected with exon 2 primers. Primer extension analysis with an intron 2 primer detected products at greater abundance in nonmacrophages. Templates detected with the intronic primer were induced in macrophages by LPS, PMA, and CSF-1, suggesting that each of the agents causes a shift from full-length c-fms mRNA production to production of unspliced, truncated transcripts. The c-fms promoter functioned constitutively in the RAW264 macrophage cell line, the B-cell line MOPC.31C, and several nonhematopoietic cell lines. Macrophage-specific expression and responsiveness to selective repression by LPS and PMA was achieved by the incorporation of intron 2 into the c-fms promoter-reporter construct. The results suggest that expression of the c-fms gene in macrophages is controlled by sequences in intron 2 that act by regulating transcription elongation.

Macrophage colony-stimulating factor 1 (CSF-1) promotes the survival, proliferation, and differentiation of cells of the mononuclear phagocyte series (29). Its biological activities are mediated by binding to a plasma membrane receptor, the product of the c-fms proto-oncogene, which is a ligand-dependent protein tyrosine kinase (24). Expression of c-fms mRNA and CSF-1 binding activity is largely restricted to mononuclear phagocytes and placental trophoblasts (24). Although there has been considerable progress in understanding tissue-specific gene expression in other hematopoietic cell lineages, macrophage differentiation remains poorly understood at the level of gene transcription. The most extensive studies have been of the lysozyme gene in chickens, which is controlled by a complex interaction between macrophage-specific enhancer elements and silencers that restrict gene expression in nonmacrophages (10). The paucity of information about macrophage-specific gene expression has been attributed to the difficulty of obtaining high transfection efficiencies with primary mammalian macrophages or myelomonocytic cell lines (25), a technical obstacle that we have recently overcome in a study of the constitutive elements controlling the expression of the urokinase plasminogen activator gene in macrophages (3). The limited literature on macrophage-specific gene expression has been largely dependent upon the use of transgenic animals (2, 25), which places limitations on detailed analysis of cis-acting sequences. Preliminary characterization of the human gene encoding c-fms revealed that in the two cell types that express the gene, trophoblasts and macrophages, transcription is initiated from two separate promoters, separated by a 25-kb intron (30). A limited analysis of transcriptional regulation of the two promoters in human cell lines (20) suggested that a 550-bp segment flanking exon 2 can direct macrophage-specific expression of a reporter gene. In this report, we show that the murine c-fms gene contains a constitutive promoter and that production of full-length mRNA is controlled by sequences in intron 2 that regulate transcript elongation.

MATERIALS AND METHODS

Cell lines and cell culture. The cell lines RAW264, Lewis lung carcinoma (LLC1 or LL/2), L929 (fibrosarcoma), BALB/3T12-3 (embryonic fibroblasts), BALB/c 10ME HD.A 5R.1 (methylcholanthrene-transformed fibroblasts), BALB/c CI.7 (embryonic fibroblasts), and MOPC.31C were obtained from the American Type Culture Collection. They were maintained in RPMI 1640 plus 10% fetal bovine serum. Primary bone marrow-derived macrophages (BMDM) were produced by cultivation of murine femoral bone marrow cells in recombinant human CSF-1 (a gift from Chiron Corp.) as described previously (14, 15). Lipopolysaccharide (LPS; Re595 from Salmonella minnesota) and phorbol myristate acetate (PMA) were obtained from Sigma.

Mouse c-fms genomic clone isolation and plasmid construction. A mouse genomic DNA library from the A17 murine T-cell lymphoma cell line in λEMBL3A (a gift from Mark

* Corresponding author.
Hogarth) was screened with a 5′ restriction fragment of the murine c-fms cDNA (21) kindly provided by Larry Rohrschneider. A clone containing a 14-kb SalI insert was isolated, the restriction map of which was consistent with the identity of this clone as the SalI genomic DNA fragment which encompasses the 5′ end of the murine c-fms gene (9). A 7-kb EcoRI fragment bracketing the 5′ end of the gene was subcloned into pBluescript (Stratagene) to yield pXYfms1, and subfragments were sequenced by the dideoxy-chain termination method, using a Pharmacia T7 polymerase kit and double-stranded plasmid templates. The 3′ ApaI site in this clone is at position 134 in the murine cDNA sequence (21). The restriction map of this fragment is presented in Fig. 7, in the context of the analysis of reporter constructs. Chloramphenicol acetyltransferase (CAT) reporter constructs were generated by subcloning the desired restriction fragments from the ApaI genomic DNA fragment in pBluescript into the multiple cloning site of the vector, placed upstream of the multiple cloning site. In addition, pGL2-Basic, the pGL6.7flns, the DNA clone were also cloned into the multiple cloning site of this vector. In the case of the intron-containing fragment and inserted into the same site in pGL2-Basic. This plasmid is referred to as pXYflnsl fragment and inserted into the pCAT-Basic. The 5′ SpeI site in this case is approximately 50 bp into the c-fms promoter sequence, while the 3′ SpeI site is in the pBluescript multiple cloning site. Plasmid pGL2-Control, containing the simian virus 40 (SV40) early promoter and enhancer, was used in some experiments. Because this vector displayed some apparent tissue specificity, another control vector was produced by inserting the EcoRI-Alul fragment of the human β-actin promoter (see above) into the multiple cloning site of pGL2-Basic. This plasmid is referred to as pGL-HBAP.

Results. RNA extraction, RNase protection, and primer extension analysis. RNA was isolated by the method of Evans et al. (8). Briefly, cells were lysed by shearing in 8 M guanidine-HCl–0.3 M sodium acetate–1% sarcosyl. After centrifugation, the supernatant was ethanol precipitated, and the pellet was suspended in 8 M guanidine–0.3 M sodium acetate, reprecipitated, washed twice with 70% ethanol, and dissolved in Tris-EDTA buffer. Primer extension was performed exactly as described by Sambrook et al. (22) except that N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES) buffer was substituted for piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES). Superscript RNase H− Moloney murine leukemia virus reverse transcriptase was obtained from Bethesda Research Laboratories. The following primers were used (their positions in the c-fms gene are described in Results): primer A, 5′-TTGGAGAGTGGCAGGAGGAGCGGGCTCCACGCTGCTTGTTC; primer B, 5′-ATGCCCAAACTGTTGCGACGGAGGACAGGGAGGCCCC; primer E, 5′-CCATTGGGTGCCCCACGTAGCTGATTGAAGGCCCAG; and primer F, 5′-AGGCGATCACCAGACAGCAGCTGGCTTTGGCAACACTCCCCC.

At the end of the reaction, 20 μl of 1 M NaOH was added to the 30-μl incubation, and the RNA template was hydrolyzed for 15 min at 65°C before neutralization with 20 μl of 1 M HCl plus 20 μl of 1 M Tris-HCl (pH 7.6). The transcribed DNA was recovered by ethanol precipitation and separated by electrophoresis on 6% polyacrylamide–8 M urea sequencing gels in parallel with a sequencing ladder generated by using the same primer and lpxfms1 as a template.

For RNase protection assays, a 410-bp c-fms genomic DNA fragment (XbaI [−203] to SmalI [+270]) or a 200-bp 5′ cDNA fragment (EcoRI in the host vector to BsrEII at bp 186 [21]) was cloned into pBluescript. A 32P-labeled antisense RNA probe was synthesized by using T3 RNA polymerase. For dot blot hybridization, a sense probe was also synthesized by using T7 RNA polymerase and treated identically. The reaction mixture contained 2 μg of template DNA in 100 μl of reaction buffer (40 mM Tris- HCl [pH 7.6], 6 mM MgCl2, 2 mM spermidine, 5 mM NaCl, 10 mM dithiothreitol, 200 μg of bovine serum albumin per ml, 500 μg ATP, CTP, and GTP, 25 μg UTP, 10 μg [α-32P]UTP [10 μCi; 800 Ci/mmol; New England Nuclear]). The reaction was terminated by addition of DNase I, the products were separated on 5% polyacrylamide gels, and the labeled probe band was excised and eluted overnight in 50% deionized formamide. The probe (50,000 cpm) was added to 10 μg of DNase I-treated RNA, precipitated in 70% ethanol, and redissolved in 20 μl of 4 mM HEPES (pH 6.4)–0.1 mM EDTA–40 mM HCl–80% deionized formamide. After heating to 85°C for 15 min, the mixture was cooled to 45°C and allowed to hybridize overnight. Then 350 μl of RNase buffer (10 mM Tris-HCl [pH 7.5], 5 mM EDTA, 300 mM NaCl, 0.4 μg of RNase T1, 8 per ml, μg of RNase A per ml) was added, and the mixture was incubated for 30 min at 37°C. The reaction was stopped by addition of 20 μl of 10% sodium dodecyl sulfate (SDS) plus proteinase K (final concentration, 12.5 μg/ml) and incubation for 30 min. Following phenol-chloroform extraction and ethanol precipitation in the presence of 20 μg of tRNA, the protected bands were separated on 8% polyacrylamide sequencing gels.

Transient transfection. Transient transfections and CAT assays were carried out as previously described (3). Briefly, 5 × 104 cells in 250 μl were transfected by electroporation at 750 V/cm (0.4-cm cuvettes) and 960-μF capacitance in RPMI 1640–10% fetal calf serum at room temperature and returned immediately to culture at 37°C. After 24 h for luciferase or 48 h for CAT assays, cells were harvested and assayed for reporter gene activity. The luciferase activity was assayed by using reagents supplied by Promega and measured with a Berthold luminometer. Activities were normalized to cell protein assayed by using a Bradford microprotein assay with reagents supplied by Bio-Rad.

RESULTS

c-fms promoter sequence. Figure 1 shows the DNA sequence of the mouse and human c-fms genes flanking exon 2. Because of the heterogeneous transcription initiation sites identified below, the two sequences are numbered relative to the initiation codon. Between −169 and −110, the alignment is tenuous, as both species have an extended polyurine tract in which the mouse includes 24 consecutive A residues. The alignment between the two species is also interrupted around −250 by the insertion in the mouse of a short GT repeat that is absent from the human gene. Beyond the conserved region shown, there is no obvious homology between the next 250 bp of mouse sequence and 600 bp of human sequence (not shown). In this region, the human gene contains an Alu repeat (20). The most conserved parts of the
I-treated RNA from murine BMDM (Fig. 2). Primer extension using a 40-bp oligonucleotide (primer A) complementary to the 5' end of the reported murine cDNA sequence (~75 in Fig. 1) (21) revealed numerous candidate transcription start sites (Fig. 2A). No bands were observed when nucleotides were omitted from the reverse transcriptase reaction (Fig. 2A) or when rRNA was used as a template (not shown). The major candidate transcription start sites are indicated in Fig. 1. While some of them correlate exactly with those identified in human monocyte-like cells (20), others extend further upstream. The same pattern of transcription start sites was observed when RNA from the macrophage cell line RAW264 was used (Fig. 2A). Surprisingly, identical primer extension products at comparable abundance were also produced with use of RNA from nonmacrophage cell lines such as the B-lymphocyte cell line MOPC.31C (Fig. 2A). To eliminate the possibility of artifact, the primer extension was repeated with use of a second 40-bp oligonucleotide (primer B) which hybridized to the end of the second exon, approximately 80 bp 3' of primer A. Again, the same products at comparable abundance were obtained with use of RNA from primary macrophages, RAW264 cells, and MOPC.31C B cells (Fig. 2B). Evidence for this lack of specificity was extended to nonhematopoietic cells, L929 fibrosarcoma (Fig. 2B) and Lewis lung carcinoma (not shown). Finally, when primer E, complementary to the 5' end of exon 3, was used, extension products were generated from primary macrophage or RAW264 RNA (Fig. 2C) but not from MOPC.31C, Lewis lung carcinoma (Fig. 2C), or L929 (not shown) RNA. This finding suggested that c-fms transcripts are initiated in nonmacrophages but terminate before the beginning of exon 3.

c-fms mRNA is down-regulated in macrophages by the lipid, CSF-1, and by bacterial LPS and phorbol esters (PMA) (11, 23). The actions of LPS are associated with cessation of c-fms-specific transcription in nuclear run-on transcription assays (11). We confirmed that each of these agonists down-regulated c-fms mRNA in BMDM and RAW264 cells by Northern (RNA) analysis (data not shown, but see also Fig. 6). Figure 3 shows the result of primer extension analysis with RNA from BMDM starved of CSF-1 (Fig. 3A) and the macrophage cell line RAW264 was used (Fig. 2A). Surprisingly, identical primer extension products at comparable abundance were also produced with use of RNA from nonmacrophage cell lines such as the B-lymphocyte cell line MOPC.31C (Fig. 2A). To eliminate the possibility of artifact, the primer extension was repeated with use of a second 40-bp oligonucleotide (primer B) which hybridized to the end of the second exon, approximately 80 bp 3' of primer A. Again, the same products at comparable abundance were obtained with use of RNA from primary macrophages, RAW264 cells, and MOPC.31C B cells (Fig. 2B). Evidence for this lack of specificity was extended to nonhematopoietic cells, L929 fibrosarcoma (Fig. 2B) and Lewis lung carcinoma (not shown). Finally, when primer E, complementary to the 5' end of exon 3, was used, extension products were generated from primary macrophage or RAW264 RNA (Fig. 2C) but not from MOPC.31C, Lewis lung carcinoma (Fig. 2C), or L929 (not shown) RNA. This finding suggested that c-fms transcripts are initiated in nonmacrophages but terminate before the beginning of exon 3.

c-fms mRNA is down-regulated in macrophages by the ligand, CSF-1, and by bacterial LPS and phorbol esters (PMA) (11, 23). The actions of LPS are associated with cessation of c-fms-specific transcription in nuclear run-on transcription assays (11). We confirmed that each of these agonists down-regulated c-fms mRNA in BMDM and RAW264 cells by Northern (RNA) analysis (data not shown, but see also Fig. 6). Figure 3 shows the result of primer extension analysis with RNA from BMDM starved of CSF-1 (which maximally up-regulates c-fms mRNA) and then treated with CSF-1, LPS, or PMA. Using the exon 2 primer (primer B), no effect of CSF-1, LPS, or PMA on the yield of primer extension products was observed. Conversely, when primer E (at the beginning of exon 3) was used, there was a clear decrease in the yield of all of the extension products in response to each of the three agonists. The magnitude of this decrease is indicated by quantitation of the total radioactivity incorporated into extension products with use of an AMBIS Radioanlyser (Fig. 3). The same pattern of results was obtained with use of the three stimuli on RAW264 cells (not shown).

If there is a block to transcription elongation prior to the beginning of exon 3 in nonmacrophages and in macrophages treated with agonists, it should be possible to detect transcripts containing intron 2. To investigate this possibility, the sequence of the mouse gene early in intron 2 was ascertained. Sequencing of this region was particularly difficult because of extensive secondary structure which was not resolved by using Taq polymerase at higher temperature. Readable sequence required the use of deaza-dGTP and 8 M urea–30% formaldehyde denaturing gels. Alignment of the mouse and human sequences in this region reveals low-level homology (Fig. 4). Regions of transcription attenuation in eukaryotic genes have commonly been associated with GC-
rich elements containing dyad symmetry which might potentially form stable stem-loops in transcribed RNA or single-stranded DNA (27). The intronic sequences of both the mouse and human c-fms genes contain extended GC-rich repeats. Potential stem-loops formed by these repeats are shown in Fig. 4 and compared with the TAR region of the human immunodeficiency virus, a known stable secondary structure (27).

Primer extension was repeated by using a primer (primer F) based upon the intron 2 sequence around the predicted stem loop in Fig. 4. Identical primer extension products were detected in all cell types examined, except BMDM starved of CSF-1 to maximally up-regulate c-fms mRNA (Fig. 5). In these cells, the level of intron-containing RNA was much lower but was increased by each of the agonists, LPS, PMA, and CSF-1, shown to down-regulate full length c-fms mRNA (Fig. 3). The data suggest that the level of intron-containing transcripts varies inversely with the level of full-length c-fms transcripts and are consistent with the existence of a site of selective transcription elongation within intron 2.

In an attempt to identify the sites of transcription attenuation in intron 2 and to independently validate the primer extension results, we performed RNase protection studies. c-fms genomic DNA extending from −203 to +210 was cloned into pBluescript, and a radiolabeled RNA probe was generated by using T3 RNA polymerase. Both BMDM and RAW264 RNA protected the labeled probe against RNase digestion, producing multiple protected bands (Fig. 6A). The position of these bands relative to the splice donor site at the end of exon 2 correlated precisely with the clustered transcription start sites identified by primer extension in Fig. 2. RNA obtained from BMDM treated with CSF-1, LPS, or PMA was less effective in producing all of the protected bands, indicating that the abundance of each of the bands correlates with the abundance of full-length c-fms mRNA. When RNA from L929, Lewis lung carcinoma, or MOPC.31C cells was used, no protected bands were detected even when the amount of RNA added was increased to 50 μg and the autoradiographs were exposed for a prolonged period (data not shown).

Because of the extensive GC-rich inverted repeats in exon 2 and the beginning of intron 2, we reasoned that internal stem loops in the intron-containing truncated transcripts could be interfering with efficient hybridization. To eliminate these potential structures from the probe, we prepared a new probe template by subcloning the 5′ end of murine c-fms cDNA (21) to the BseFII site at bp 186 into pBluescript. With labeled antisense RNA transcribed from this segment used
as a probe, RNA from BMDM or RAW264 cells generated the expected 186-base protected band, but it was still impossible to detect any protected bands when nonmacrophage RNA was used (data not shown).

The only way to eliminating secondary structures from the transcripts is to denature and immobilize them. Accordingly, the 5' c-fms antisense RNA probe was used in a dot blot hybridization on macrophage and nonmacrophage RNA bound to nitrocellulose membranes. The result (Fig. 6B) indicates that macrophages and nonmacrophages do indeed contain approximately equal levels of transcripts that hybridize to the 5' end of c-fms. Furthermore, as suggested by the primer extension data in Fig. 3, CSF-1, LPS, and PMA had no significant effect on the abundance of transcripts detected with the 5' c-fms probe. The reasons why short transcripts cannot be detected in nonmacrophages by RNase protection are considered in Discussion.

**FIG. 3.** Effects of CSF-1, LPS, and PMA on c-fms transcription attenuation in BMDM. BMDM were washed and incubated overnight in the absence of CSF-1 to maximally induced c-fms mRNA. They were then incubated for 4 h with CSF-1 (1,000 U/ml), LPS (100 ng/ml), or PMA (10⁻⁷ M) prior to RNA isolation. RNA (50 μg) from each treatment was incubated with radiolabeled primer B (end of exon 2) or primer E (beginning of exon 3) and extended with reverse transcriptase. The extension products were separated on a sequencing gel in parallel with a sequencing reaction. Quantitation was achieved by scanning the entire gel with an AMBIS Radioanlyser and counting the total radioactivity in the extension products in each lane. The results expressed as total counts per minute are displayed below each lane.

Transient transfection analysis. The expression of similar levels of presumptive short c-fms transcripts in macrophages and nonmacrophages implies that the c-fms promoter is not tissue specific. Promoter specificity was assayed directly by transient transfection using reporter gene constructs linking the CAT gene to the c-fms promoter. Because of the heterogeneity of transcription start sites identified in Fig. 2, most of the constructs were designed to include the entire 5' untranslated region of c-fms by retaining the c-fms initiation codon. In the first experiment, a series of CAT reporter construct deletions was transfected into RAW264 cells. The most extensive construct contained ca. 3.5 kb of 5' flanking sequence. Sequential deletion of the 5' flanking sequence produced little alteration of the level of reporter gene expression (Fig. 7a). Even deletion to −200 reduced but did not abolish the constitutive activity in RAW264 cells. 3' truncation of the promoter to −63 (Fig. 1) (which means that the CAT rather than the c-fms initiation codon is used) also had little effect. This construct is comparable to the human c-fms promoter constructs used by Roberts et al. (20) in which the

**FIG. 4.** Sequence analysis of the second intron of murine c-fms. (A) Sequence of murine c-fms. New sequence starts at the splice site indicated by an arrow, which is in the identical position of the human gene. Significant alignment with the human c-fms genomic sequence obtained from EMBL (accession number X14720) was determined by using MacVector software. Both species contain a long inverted repeat between the bases indicated by the squares (mouse) and circles (human). These sequences have the potential to form stable stem-loops in transcribed RNA or single-stranded DNA as indicated in panel B. The stem-loop structure formed by the human immunodeficiency virus (HIV) TAR region is shown for comparison (see Discussion).
CAT gene was fused at -57. Treatment of the RAW264 cells transfected with the reporter constructs with PMA had no effect on CAT activity (Fig. 7a). The activities of long (pFMS3.5CAT) and short (pFMS0.3CAT) c-fms reporter constructs were also tested in nonmacrophages, using a \( \beta \)-actin promoter-CAT construct as a transfection control. The relative activities of the two c-fms constructs did not distinguish RAW264 cells from the B-cell line MOPC.31C or any of the nonhematopoietic murine tumor cell lines tested (Fig. 8).

To address the role of intron 2 in generating tissue specificity, the c-fms genomic DNA fragments were transferred to the luciferase reporter construct, pGL2-Basic. Apart from the availability of a more convenient set of...
FIG. 7. (a) Transient transfection analysis of the activity of the c-fms promoter, using CAT reporter gene constructs. Cells were transfected with 10 μg of reporter plasmid by electroporation (see Materials and Methods), and CAT expression was assayed after 48 h. The map of the reporter constructs is shown in panel b, and the restriction map of the 7-kb ApaI genomic DNA fragment encompassing the 5' end of the murine c-fms gene is shown in panel c. Restriction enzyme sites: A, ApaI; S, SacI; P, PvuII; H, HaeIII; X, XbaI; Xh, XhoI; Ev, EcoRV. In panel a, RAW264 cells were transfected with each of the constructs; then 10^-7 M PMA was added to half the cells (shaded bars), while the remainder were untreated (solid bars). The results are averages of two separate experiments, each of which involved two separate transfections and separate preparations of plasmid.
FIG. 8. Comparison of the activities of the short (pFMS0.3CAT) and long (pFMS3.5CAT) c-fms promoter constructs in macrophages (RAW264 cells) and a range of nonmacrophage lines with that of the positive control plasmid pH8AP-CAT. In each case, the cells were transfected by electroporation with 10 μg of plasmid, and CAT activity was assayed 48 h later. The results are averages of duplicate transfections and are representative for each of the cell lines.

Restriction sites in the multiple cloning site, pGL-Basic, provided a much lower negative control than did pCAT-Basic. Figure 9A compares the activities of three constructs, a 0.3-kb c-fms promoter, a 3.5-kb c-fms promoter, and a minigene construct (pGL6.7/fms) containing the 3.5-kb 5' flanking sequence plus the whole of intron 2 and the beginning of exon 3. The results obtained with the first two constructs confirm those obtained with the CAT vectors; the activity of the c-fms promoter relative to the β-actin promoter did not clearly distinguish macrophages from nonmacrophages. The inclusion of the intron 2 sequences reduced reporter gene expression in RAW264 cells but almost completely abolished activity in MOPC.31C, L929, and Lewis lung carcinoma cells. Also shown in Fig. 9A is the comparative activity of the SV40 early promoter and enhancer in the positive control vector pGL-Control. The β-actin promoter was slightly less active in MOPC.31C cells than in RAW264 cells and less again than in L929 and Lewis lung carcinoma cells. We have confirmed that the levels of β-actin mRNA and the rate of transcription of the β-actin gene in run-on transcription assays are similar in each cell population (not shown), so the expression of this construct provides some indication of transfection efficiency in each case. By contrast, pGL-Control (the SV40 early promoter) was 20- to 50-fold more active in MOPC.31C cells than in RAW264 cells, and in L929 and Lewis lung carcinoma cells, it was a further 10-fold less active. These data suggest that the SV40 enhancer contains tissue-specific cis-acting elements.

The results of the primer extension experiments in Fig. 3
FIG. 9. Transient transfection analysis of the activity of the murine c-fms promoter, using luciferase promoter constructs. Cells were transfected by electroporation with 10 μg of plasmid as described in Materials and Methods. pGL0.3flms and pGL3.5flms contain the same promoter fragments as do the corresponding CAT vectors in Fig. 7 and 8. pGL6.7flms contains the entire Apal genomic DNA fragment from pXTfms1, so that the reporter gene is fused into exon 3. It is therefore identical to pGL3.5flms except for the inclusion of intron 2 and exon 3. In each case, cells were returned to medium at 37°C immediately posttransfection and harvested after 24 h for the assay of luciferase activity. (A) Comparison of the activity of each of the c-fms constructs with the promoterless luciferase parent vector (pGL2-Basic), the SV40 promoter (pGL2-Control), and the β-actin promoter (pGL-HBAP). In some panels, the results from control plasmids are off scale and are presented in units of 10 RLU as indicated. Note that the activity of pGL6.7flms in the nonmacrophages is not significantly different from the activity of the promoterless plasmid, pGL2-Basic. The results are averages of duplicate transfections and are representative of three experiments. (B) Effects of LPS (500 ng/ml), PMA (1 μg/ml), and CSF-1 (104 U/ml) added immediately posttransfection on the activity of the three flms promoter plasmids. In each case, cells from a single transfection were divided into four wells prior to addition of agonist; results are averages of two separate transfections. In both of the experiments shown, PMA and LPS induced the activity of the SV40 promoter construct (pGL2-Control) two- to fivefold but had no effect on the activity of the β-actin promoter, while CSF-1 had no effect on the activity of any promoter. RLU, relative light units.

and 5 suggest that CSF-1, LPS, and PMA reduce c-fms mRNA levels in macrophages by blocking transcription elongation within intron 2. Figure 9B shows the effects of the three agonists on c-fms promoter activity, using the luciferase reporter constructs above. CSF-1 had no effect in transient transfections with any of the reporter plasmids, which may reflect an artifact of transient transfection. In another study, we showed that the introduction of DNA into macrophages prevents them from responding to CSF-1 with increased growth (28) and prevents induction of the CSF-1-responsive urokinase plasminogen activator promoter (27a). By contrast to the data obtained with the CAT reporter constructs, PMA exerted a slight inhibition of the activity of the longer (3.5-kb) c-fms promoter but had a far more marked effect on the activity of the construct containing intron 2. LPS was more selective; it caused no inhibition of the activity of the 3.5- or 0.3-kb c-fms promoter but reduced the activity of the intron-containing construct three- to fivelfold. The effects of the two agents were selective. In transfections parallel to those shown in Fig. 9, the SV40 promoter in pGL-Control was actually trans activated by LPS and PMA, whereas the β-actin promoter was relatively unaffected (not shown).

DISCUSSION

The c-fms gene in humans is closely linked to the gene encoding the platelet-derived growth factor (PDGF) receptor on chromosome 5 (20). Exon 1, located less than 500 bp downstream of the PDGF receptor gene, is transcribed only in trophoblasts and choriocarcinomas (20, 30). In human monocyte cell lines, transcription initiates immediately 5' of exon 2, which contains the initiation codon. Figures 1 and 2 show that the sequences of the mouse and human c-fms genes adjacent to exon 2 are conserved and that murine primary macrophages and the macrophage line RAW264 produce transcripts initiated at a cluster of transcription start sites in this region. These data are consistent with analysis of the human c-fms gene in macrophages (20), which identified a similar diversity of transcription start sites. The presence of multiple clustered transcription starts is common in TATA-less promoters (1, 26). The other element typically involved in specifying accurate transcription initiation is the CCAAT box, which is usually placed 50 to 90 bp upstream of the transcription start site (6). The repeated CCAAT-like motif around 60 to 100 bp from the multiple transcription start sites of c-fms, although it does not fit the CCAAT box consensus sequences, does bind multiple DNA-binding proteins in all cell lines tested, including at least one nuclear protein that also binds the CCAAT box sequence of the ubiquitously active H2-K promoter (unpublished data).

Taken together, the transient transfection and reverse transcriptase primer extension analyses in Fig. 2, 3, 5, 7, 8, and 9 suggest that expression of full-length c-fms mRNA in macrophages is controlled primarily by sequences in intron 2 that probably mediate tissue-specific transcription elongation. This conclusion contrasts with the claim that the homologous human c-fms promoter directs monocyte-specific expression of a CAT reporter gene in transient transfection analysis (20). Given the substantial homology between the promoters from the two species (Fig. 1) and the conserved patterns of expression, it seems unlikely that this
contrast reflects a genuine species difference. One possibility is that the SV40 enhancer included at the 3' end of the CAT gene in the human c-fms reporter constructs (20) confers tissue specificity as well as detectability. This possibility is favored by the data in Fig. 9A, which suggest that the SV40 promoter plasmid is tissue specific. An alternative view of the regulation of c-fms during human monocye/macrophage differentiation derives from the work of Weber et al. (32), who suggested that the gene is controlled via differential differentiation. Furthermore, Gusella et al. (11) showed the apparent presence of short c-fms transcripts in nonmacrophages by dot blot hybridization (Fig. 6B) indicate that short transcripts are as abundant in nonmacrophages as in the full-length mRNA in macrophages, they could not be detected by Northern blotting with a cDNA or a genomic DNA probe (not shown), and no bands protected from S1 nuclease were detected in nonmacrophages in the published studies of the human c-fms gene (20, 30). Similarly, we could not detect the short transcripts in nonmacrophages by RNase protection (Fig. 6A). In every case in which the 3' ends of attenuated transcripts have been identified, they are extremely heterogeneous (27) even when analyzed in cell-free transcription assays (16). Since the 5' ends of the c-fms transcripts are also heterogeneous, part of the reason they cannot be detected in Northern blots or nuclease protection may be that they do not form a definable band on a gel. An additional problem influencing detection of the short transcripts by nuclease protection is the abundance of extended GC-rich inverted repeats in exon 2 and the beginning of intron 2. In fact, the mouse sequence from -70 to +110 contains 63% GC residues. GC-rich stem-loops in both DNA and RNA are remarkably stable (13). Furthermore, there is the potential for interchain hybridization between short c-fms transcripts because of the inverted repeats. The existence of duplexes and stem-loops in short c-fms transcripts would probably reduce hybridization in nucleic protection assays, and any regions of mismatch or loop formation would not be protected from cleavage.

Those attenuators that have been characterized in prokaryotic and eukaryotic systems often contain GC-rich motifs with dyad symmetry (27). The c-fms sequences in exon 2, early in intron 2 (Fig. 4), and in exon 3 (mouse cDNA bp 127 to 139; 5'-CAGGGGGCCCTG-3') clearly resemble other attenuator sequences, including those of the c-fos gene (5'-TCCCCGGCCGGA-3') (18), the c-myc gene (5'-GCCCCGTGGG-3') (19), and the TAR region of human immunodeficiency virus type 1 (as shown in Fig. 4). Homologies between c-fms sequences and the c-fos and c-myc terminators may be of functional significance. The c-fos attenuator is apparently involved in the regulation of c-fos transcription elongation in macrophages (7). c-myc is expressed in myeloid progenitor cells, and transcriptional elongation is down-regulated during myeloid differentiation (19). There might conceivably be a link between the control of transcription elongation of c-myc and c-fms.

In summary, we have provided evidence that tissuespecific expression of the murine c-fms gene in macrophages and its regulation by specific agonists involves sequences in intron 2 that probably control transcription elongation. Because c-fms is the receptor for the major macrophage growth and differentiation factor CSF-1, selective elongation of c-fms transcripts may be viewed as the rate-limiting event in macrophage differentiation.

REFERENCES